For many decades, changes in blood coagulation have been recognized to occur during treatment with a (heart) lung machines (ECMO), yet the underlying mechanisms are not well understood. Changes in blood coagulation may clinically manifest both by "blood clots" such as thromboembolism, e.g., in the form of strokes, as well as by a bleeding tendency, e.g., in the form of cerebral or pulmonary haemorrhage. These complications may negatively affect the treatment outcome and in some cases even be the reason for death. Therefore, the aim of this study is to better understand the changes in coagulation during ECMO treatment in order to prevent these complications and, if they do occur, to be able to treat them specifically.

Here you can find further information.